| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 08/17/2005 | CN1655786A Combination of a DPP IV inhibitor and a cardiovascular compound |
| 08/17/2005 | CN1655785A N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders |
| 08/17/2005 | CN1655784A Use of compounds that are effective as selective opiate receptor modulators |
| 08/17/2005 | CN1655774A Bis-aromatic alkanols |
| 08/17/2005 | CN1655770A Chewable soft capsule |
| 08/17/2005 | CN1655768A Oral dosage form for controlled drug release |
| 08/17/2005 | CN1655764A Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| 08/17/2005 | CN1654639A Recombinant asparaginase with function of preventing and curing diabetes mellitus |
| 08/17/2005 | CN1654481A Process for preparing glucose-reducing sand sagebrush polysaccharide and its use |
| 08/17/2005 | CN1654480A Soluble highly branched glucose polymers |
| 08/17/2005 | CN1654059A Application of 'Kidney Benefiting Injection' in the process for preparing medicine to treat diabetic nephropathy |
| 08/17/2005 | CN1654042A Method for preparing natural organic silk worm protein for improving insulin excretion in diabetes patients |
| 08/17/2005 | CN1654041A Application of eagle-tea extract total flavone in preparation of medicine for blood fat regulating |
| 08/17/2005 | CN1215076C Heteroaromatic inhibitors of fructose 1, 6-bisphosphatase |
| 08/17/2005 | CN1215067C 哒嗪酮醛糖还原酶抑制剂 Pyridazinone aldose reductase inhibitors |
| 08/17/2005 | CN1215059C Novel heterocyclic compounds and salts thereof and medicinal use of same |
| 08/17/2005 | CN1214817C Coupling factor 6 inhibitor and potentiator and use thereof |
| 08/17/2005 | CN1214814C Capsule prepn for regulating blood fat and blood sugar |
| 08/17/2005 | CN1214790C Method for preparing isoxazole substituted composition for treating inflammation |
| 08/16/2005 | US6930207 derivatives which inhibit pancreatic lipase and therefore can be used in combating or preventing obesity and hyperlipaemias |
| 08/16/2005 | US6930123 Benz(f)indole compounds useful for Inflammatory Diseases |
| 08/16/2005 | US6930120 Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists |
| 08/16/2005 | US6930111 Substituted heterocyclic compounds |
| 08/16/2005 | US6930108 Nitrogen compounds such as 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one, used for prophylaxis of psoriasis, diabetes, alopecia, genetic, sexual, cardiovascular or genetic disorders |
| 08/16/2005 | US6930105 Tetracyclicazaindoles and indolines having 5-HT activity |
| 08/16/2005 | US6930101 Thiazolopyrimidines useful as TNFα inhibitors |
| 08/16/2005 | US6930091 growth and activity promotion effects on osteoblasts |
| 08/16/2005 | US6930088 Conformationally constrained backbone cyclized somatostatin analogs |
| 08/16/2005 | US6929955 Interactive system for presenting and eliminating substances |
| 08/16/2005 | US6929817 Slowly digestible starch product |
| 08/16/2005 | US6929808 Isolating modulators of amyloid expression; obtain plant, extract proteins, incubate with chromatographic column, elute, recover preferential protein |
| 08/16/2005 | US6929793 Nutritional composition for treating an immune condition |
| 08/16/2005 | CA2342974C Methods and compositions for inhibition of angiogenesis |
| 08/16/2005 | CA2220438C (n-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents |
| 08/11/2005 | WO2005073398A1 Method of assaying capability of inhibiting fat level increase |
| 08/11/2005 | WO2005072767A1 Agent for improving sugar metaboic function |
| 08/11/2005 | WO2005072757A1 Imperatae rhizoma extract for treatment and prevention of obesity |
| 08/11/2005 | WO2005072750A1 Composition for inhibting dietary lipid absorption |
| 08/11/2005 | WO2005072714A1 Oral administration of r-albuterol against obesity |
| 08/11/2005 | WO2005072066A2 Preventive or therapeutic agent for diabetic maculopathy |
| 08/11/2005 | WO2005072045A2 The combined use of glp-1 agonists and gastrin for regulating blood glucose levels |
| 08/11/2005 | WO2004103276A3 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 08/11/2005 | US20050176964 Nicotinamide derivatives useful as p38 inhibitors |
| 08/11/2005 | US20050176927 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, agonists, and antagonists; drug screening; diagnosis |
| 08/11/2005 | US20050176828 Polyamine acylated with a hydrophobic acyl group, where acylation is by formation of either an amide or a sulfonamide linkage; antiproliferative agents; inhibition of cellular polyamine synthesis, even in the presence of exogenously supplied spermidine to inhibit cell growth and proliferation |
| 08/11/2005 | US20050176821 Meta-substituted phenylene sulphonamide derivatives |
| 08/11/2005 | US20050176817 Anticancer agents; prevention of infections; autoimmune diseases;antiarthritic agents; cystic fibrosis |
| 08/11/2005 | US20050176816 Controlling infections; antiallergens; antiarthritic agents; cardiovascular disorders |
| 08/11/2005 | US20050176815 Malaria therapy |
| 08/11/2005 | US20050176813 Modulating the potassium ion channel activity of T-cells; autoimmune and inflammatory diseases such as multiple sclerosis, rheumatoid arthritis or transplant rejection; synthesis by reaction of an acetophenone such as khellinone with an aryl aldehyde |
| 08/11/2005 | US20050176806 Use of 1-[3-hydroxy-1-adamantylamino]acetyl-2-cyano-pyrrolidine, for example with other anticholesterol drugs such as statins |
| 08/11/2005 | US20050176802 Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 08/11/2005 | US20050176799 drugs such as 1-Benzyl-3-(2-furyl)-5-trifluoromethylpyrazole, capable of modulating biosynthesis of cyclic guanosine monophosphate, used for therapy and prophylaxis of cardiovascular disorders such as hypertension, angina pectoris, cardiac insufficiency, thrombosis or atherosclerosis |
| 08/11/2005 | US20050176771 4-fluoro-1-({[1-(methanesulfonyl)piperidin-4-yl]amino}acetyl)pyrrolidine-2-carbonitrile; insulin-dependent diabetes (type 1 diabetes), non insulin-dependent diabetes (type 2 diabetes), insulin-resistant disorders, obesity; dipeptidyl peptidase IV-inhibiting activity |
| 08/11/2005 | US20050176770 Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them |
| 08/11/2005 | US20050176766 2,3-Oxidosqualene-lanosterol cyclase inhibitors |
| 08/11/2005 | US20050176759 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders |
| 08/11/2005 | US20050176756 Cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters; treating pain, neurodegeneration, inflammation, and drug or alcohol withdrawal symptoms; 3-benzimidazole, indole or triazole substituted |
| 08/11/2005 | US20050176746 Treating eating disorders and digestive disorders wth loperamide |
| 08/11/2005 | US20050176731 N-[5-({(2S)-3-[(4-{4-[(4-benzylpiperidin-1-yl)carbonyl]phenyl}cyclohexyl)amino]-2-hydroxypropyl}oxy)-2-hydroxyphenyl]methanesulfonamide; beta 3 receptors agonist; gastrointestinal diseases; antiobesity, antidiabetic, cicatrizing agents, tocolytics, dysmenorrhea, antiglaucomatous; amidation |
| 08/11/2005 | US20050176722 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof |
| 08/11/2005 | US20050176720 Pharmaceutical composition for the treatment of CNS and other disorders |
| 08/11/2005 | US20050176714 Pyridazine derivatives |
| 08/11/2005 | US20050176713 Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| 08/11/2005 | US20050176711 Phthalazine derivatives for treating inflammatory diseases |
| 08/11/2005 | US20050176709 Selective NPY (Y5) antagonists |
| 08/11/2005 | US20050176708 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 08/11/2005 | US20050176700 (2-methoxyphenyl)acetic acid-7-{4-[3-(2-methoxybenzyloxy)-propoxy]phenyl}-3-(2-thiophen-2-ylacetyl)-3,9-diazabicyclo[3.3.1]non-6-en-6-yl-methyl ester; metabolically stable, orally bioavailable and sufficiently soluble; industrial scale; non-peptidic nature, low molecular weight |
| 08/11/2005 | US20050176698 Neuropeptide Y antagonists |
| 08/11/2005 | US20050176685 Administering bisphosphonate compounds such as ibandronate, minodronate, pamidronate, risedronate, zoledronate, and alendronate; osteoporosis |
| 08/11/2005 | US20050176684 5-(4-Bromo-3-aminophenyl)-2-furanphosphonic acid; fructose-1,6-biphosphatase inhibitor; diabetes type 1 and 2, glycogen storage diseases, cardiovascular diseases with increased insulin levels, atherosclerosis; in vitro, in vivo; |
| 08/11/2005 | US20050176678 Compounds and method for coating surfaces in a haemocompatibe manner |
| 08/11/2005 | US20050176673 guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections |
| 08/11/2005 | US20050176659 Polypeptide contributing to regulating the metabolism of triglycerides; obesity as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstone, cancers of the reproductive organs |
| 08/11/2005 | US20050176639 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 08/11/2005 | US20050176637 Administering a peptide having a sequence of QPLALEGSLQK in combination with another polypeptide to treat insulin dependent diabetes mellitus (IDDM or Type 1 diabetes) |
| 08/11/2005 | US20050176635 Remedy for bone mtabolic diseases |
| 08/11/2005 | US20050176630 Modification of feeding behavior |
| 08/11/2005 | US20050176622 secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of DP IV |
| 08/11/2005 | US20050176123 Protease inhibitor |
| 08/11/2005 | US20050176094 Polypeptide having immunomodulatory activity, antiviral activity, and antitumor activity; polynucleotides, expression vectors , probes and antibodies; predicting responsiveness to treatment with interferon- alpha and other interferons which act at the Type 1 interferon receptor |
| 08/11/2005 | US20050176060 Crystal structure |
| 08/11/2005 | US20050175763 Phosphatidyl serine, phosphatidyl choline and similar compounds; food for tube feeding; health-giving, performance-enhancing or disease-preventing (eg diabetes) |
| 08/11/2005 | US20050175725 Body fat percentage-lowering agent or body fat percentage increase inhibitor |
| 08/11/2005 | US20050175724 Composition for modulating at least one physiological reaction or inducing an immune response in human or animal after oral administration; for intestinal delivery of a physiologically active agent, a neutralizing agent, an inhibitor of digestive enzymes, an uptake increasing agent; synergistic |
| 08/11/2005 | US20050175639 Methods |
| 08/11/2005 | CA2595520A1 Hsp therapy in conjunction with a low antigenicity diet |
| 08/11/2005 | CA2554735A1 Therapeutic and carrier molecules |
| 08/11/2005 | CA2554527A1 Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments |
| 08/11/2005 | CA2554525A1 Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments |
| 08/11/2005 | CA2554524A1 Indazole derivatives as inhibitors of hormone-sensitive lipases |
| 08/11/2005 | CA2554522A1 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments |
| 08/11/2005 | CA2554458A1 The combined use of glp-1 agonists and gastrin for regulating blood glucose levels |
| 08/11/2005 | CA2554455A1 Anorectic |
| 08/11/2005 | CA2549029A1 Compositions for treatment or prevention of metabolic syndrome |
| 08/10/2005 | EP1561752A1 Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| 08/10/2005 | EP1561472A1 Solid preparation |
| 08/10/2005 | EP1561468A1 Pharmaceutical antidiabetic composition |
| 08/10/2005 | EP1561458A1 Rapidly disintegrable solid preparation |
| 08/10/2005 | EP1560828A1 Imidazoquinoline derivatives as adenosine a3 receptor ligands |